← Back

Dezhan HealthCare Co Ltd

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, hydroxyurea tablets, colchicine tablet, and oseltamivir phosphate capsules. It also involved in the provision of biopeptides, industrial hemp, and medical service business. Dezhan Healthcare Company Limited was founded in 1980 and is based in Beijing, the People's Republic of China.

Price · split & dividend adjusted
News & notes moving 000813.CS
000813.CS2

Dezhan Health shareholder Chen Zhiwenlong's entire stake frozen

Dezhan Health disclosed that the entire stake held by shareholder Chen Zhiwenlong, who owns more than 5% of the company, has been frozen. The number of shares frozen this time is approximately 130 million, accounting for 100% of his holdings and 6.18% of the company's total share capital. The company stated that Chen Zhiwenlong is not a controlling shareholder or actual controller, and this freeze will not affect daily operations and management.
北京商报·20dRead more ▾
000813.CS

Dezhan Health Expects First-Half Net Loss of 38 Million to 75 Million Yuan

Dezhan Health has released its 2026 semi-annual performance forecast, expecting a net loss attributable to shareholders of 38 million to 75 million yuan for the first half, compared with a loss of 42.9265 million yuan in the same period last year. The company stated that the loss is mainly due to the continued deepening of its business structure integrating pharmaceuticals, medical services, and health, increased investment in innovative research and development, and the impact of volume-based procurement policies on revenue.
北京商报·44dRead more ▾